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1422Improved Nonrelapse Mortality and Infection Rate
with Lower Dose of Antithymocyte Globulin in Patients
Undergoing Reduced-Intensity Conditioning Allogeneic
Transplantation for Hematologic Malignancies
Mehdi Hamadani,1 William Blum,1 Gary Phillips,2 Patrick Elder,1 Leslie Andritsos,1
Craig Hofmeister,1 Lynn O’Donnell,1 Rebecca Klisovic,1 Sam Penza,1 Ramiro Garzon,1
David Krugh,1 Thomas Lin,1 Thomas Bechtel,1 Don M. Benson,1 John C. Byrd,1
Guido Marcucci,1 Steven M. Devine1We sought to reduce the risk of infectious complications and nonrelapse mortality (NRM) associated with
the use of antithymocyte globulin (ATG) without compromising control of acute graft-versus-host disease
(aGVHD) in patients undergoing reduced-intensity conditioning (RIC) transplantation. As part of an ongoing
quality improvement effort, we lowered the dose of rabbit ATG from 7.5 mg/kg of ATG (R-ATG) (n5 39) to
6.0 mg/kg of ATG (r-ATG) (n 5 33) in association with fludarabine (Flu) and busulfan (BU) RIC transplanta-
tion and then monitored patients for adverse events, relapse, and survival. Of the 72 mostly high risk (82%)
patients studied, 89% received unrelated donor allografts, 25% of which were HLA-mismatched. No differ-
ences in posttransplantation full donor-cell chimerism rates were observed between the 2 ATG-dose groups
(P. .05). When R-ATG versus r-ATG patients were compared, we observed no significant difference in the
cumulative incidence of grade II-IV aGVHD (32% versus 27%; P 5 .73) or grade III-IV aGVHD (23% versus
11%; P 5 .28). However, the r-ATG group had significantly less cytomegalovirus (CMV) reactivation (64%
versus 30%; P 5 .005) and bacterial infections (56% versus 18%; P 5 .001), a better 1-year cumulative inci-
dence of NRM (18% versus 3%; P 5 .03), and a trend for better 1-year overall survival (OS) (64% versus
84%; P 5 .07) compared to R-ATG patients. A seemingly modest reduction in the dose of rabbit ATG did
not compromise control of aGVHD or achievement of donor chimerism, but led to a significant decrease
in the risk of serious infections and NRM in high-risk RIC allograft recipients.
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(HSCT) [1-3]. A variety of strategies have been devel-
oped to prevent severe GVHD following either
myeloablative (MA) or reduced-intensity conditioning
(RIC) transplantation, including ex vivo T cell deple-
tion (TCD) [4,5], in vivo TCD with antithymocyte
globulin (ATG) [1,6-10], calcineurin inhibitors [11],
and monoclonal antibodies (mAbs) [12-16], but no
consensus has been reached on the superiority of one
modality over another.
In vivo TCD by ATG administration is performed
by using 1 of the 3 commercially available ATG prod-
ucts (Thymoglobulin, ATGAM, and ATG-Frese-
nius) [17]. Despite reducing the risk for GVHD,
preliminary data suggest that higher ATG doses
seem to be associated with increased risk of disease re-
lapse, infectious complications, and nonrelapse mor-
tality (NRM) [6,10]. However, only few studies have
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lowing MA [17-19], or RIC HSCT [20], and the re-
sults of these trials have mostly been inconclusive
because of the heterogeneity of the utilized condition-
ing regimens and ATG administration schedules and
the relatively few patients analyzed.
We report here the results of quality improvement
efforts designed to compare outcomes associated with
2 moderate doses of rabbit ATG in patients undergo-
ing HSCT following uniform RIC with fludarabine
(Flu) and busulfan (BU). Our data suggest that a seem-
ingly ‘‘modest’’ reduction in rabbit ATG dose from 7.5
mg/kg to 6 mg/kg leads to a marked reduction in the
rates of infectious complications, and provides a signif-
icant NRM benefit without compromising GVHD
control, engraftment kinetics, and posttransplantation
survival.PATIENTS AND METHODS
Patient Population
Seventy-two consecutive patients with hemato-
logic malignancies undergoing allogeneic HSCT fol-
lowing uniform RIC with Flu, BU, and rabbit ATG,
between January 2006 and December 2008, were in-
cluded. All patients had adverse risk (precluding the
use of MA conditioning), which that was defined by
the presence of at least 1 of the following features:
(1) age .55 years; (2) Karnofsky performance score
(KPS) #70; (3) hematopoietic cell transplantation-co-
morbidity index (HCT-CI) .2 (4) baseline diagnosis
of Hodgkin disease (HD), or chronic lymphocytic leu-
kemia (CLL); and (5) prior history of autologous trans-
plantation. This retrospective analysis was approved
by the OSU institutional review board and Clinical
Scientific Review Committee.Quality Improvement Program
As part of our continuous quality improvement
program, we audit the rates of serious bacterial, fungal,
and viral infections as well as rates of NRM on a quar-
terly and semiannual basis, respectively. We seek to
maintain rates of serious infections (defined as cyto-
megalovirus (CMV)/Epstein-Barr virus (EBV) reacti-
vation requiring preemptive therapy, bacteremias, or
invasive fungal/viral/protozoal infections) below 50%
and NRM below 15% at 1 year in recipients of RIC
transplantation. Our standard of care (SOC) protocol
for recipients of RIC transplantation and unrelated
donor or mismatched allografts incorporated a total
dose of ATG of 7.5 mg/kg (R-ATG) given over
3 days. When our quality review committee observed
that these patients had rates of serious infections above
50% andNRMapproaching or.15%, wemade a pro-
grammatic decision to reduce the total dose of rabbitATG to 6.0 mg/kg (r-ATG)and continued to monitor
clinical events in these patients.
Conditioning Regimen, GVHD Prophylaxis, and
Supportive Care
The conditioning regimen consisted of i.v. Flu 30
mg/m2 on days 27 to 23 (total dose; 150 mg/m2) and
i.v. Bu 0.8 mg/kg/dose  8 doses, on days 24 to 23
(total dose; 6.4 mg/kg) [21]. The first cohort of 39 con-
secutive patients received rabbit ATG (Thymoglobu-
lin, Genzyme; Cambridge, MA) (R-ATG group) at
2.5 mg/kg/day, on days 24 to 22 (total dose; 7.5
mg/kg). The second cohort of 33 patients (r-ATG)
were given ATG at 2.0 mg/kg/day on the same sched-
ule (total dose; 6.0 mg/kg).
All patients received standard prophylaxis of
GVHD with tacrolimus (0.03 mg/kg/day i.v., com-
mencing on day 22) and minidose methotrexate
(MTX; 5mg/m2 on days11,13,16, and111) as pre-
viously described [22]. Blood levels of tacrolimus were
monitored weekly until day190 to maintain levels be-
tween 5 and 15 ng/mL. From day 190 onward tacro-
limus was tapered at the discretion of the treating
physician if no GVHD appeared.
All patients were treated in HEPA-filtered rooms,
and received fungal (fluconazole, or posaconazole),
herpes zoster/herpes simplex (intravenous acyclovir
or oral valacyclovir), bacterial, and Pneumocystis jiroveci
prophylaxis (trimethoprim/sulfamethoxazole [TMP-
SMX] or dapsone). Weekly monitoring for CMV
and EBV reactivation by quantitative RT-PCR was
conducted. Preemptive ganciclovir or valganciclovir
were administered to patients with CMV reactivation
(defined as $4000 copies/mL, reconfirmed within 24
hours from initial detection); preemptive single i.v.
dose of rituximab (375 mg/m2) was administered to
all patients with evidence of EBV reactivation (defined
as $4000 copies/ml, reconfirmed within 24 hours
from initial detection). EBV PCR was rechecked
1 week after rituximab administration. For patients
with negative EBV PCR at this stage, no further ritux-
imab doses were given, whereas patients with increas-
ing or persistently positive EBV PCR received 3
additional weekly rituximab doses. Urine and/or
serum BK-virus PCR was obtained in all suspected
cases of hemorrhagic cystitis. The time of neutrophil
engraftment was considered the first of 3 successive
days with absolute neutrophil count (ANC) $0.5 
109/L after posttransplantation nadir; the time of
platelet engraftment was considered the first of 3
consecutive days with platelet count $20  109/L, in
the absence of platelet transfusion.
GVHDAssessment and Treatment
Patients achieving neutrophil engraftment were
evaluable for acute GVHD (aGVHD (acute GVHD))
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were evaluable for chronic GVHD (cGVHD) if en-
graftment occurred and the patient survived for 100
days posttransplantation. The diagnoses of cGVHD
and extensive cGVHD were made as previously de-
scribed [24-26]. Corticosteroids comprised the first-
line therapy of acute (grade II-IV) and extensive
cGVHD. Second-line treatment was at the discretion
of treating physicians and included mycophenolate
mofetil, extracorporeal photopheresis, and infliximab.Statistical Analysis
Baseline categoric variables were compared by
using Fisher’s exact test, whereas continuous variables
were comparedbyWilcoxon rank-sum test or 2-sample
t-test as appropriate. Overall survival (OS) and pro-
gression free survival (PFS) were estimated using the
Kaplan-Meier method. OS was defined as the time
from transplant to death, and surviving patients were
censored at last follow-up. PFS was defined as the
time from transplantation to disease progression/re-
lapse and/or death. OS and PFS data were analyzed
by the log-rank test. NRM was defined as death from
any cause other than disease progression or relapse.
Cumulative incidences of NRM and relapse were cal-
culated with relapse or death as a competing event,
respectively [27]. Comparisons between estimates of
cumulative incidence were made by using the Gray’s
test. The cumulative incidence of aGVHDor cGVHD
was calculatingwith relapse or death without relapse or
GVHD as competing events [20,27]. Cox proportional
hazardsmodels were constructed for a cumulative inci-
dence of aGVHD, cGVHD, or NRM, relapse, and for
OS and PFS, using a limited backward selection proce-
dure. Variables considered in themodel were those sig-
nificant at a5 0.20 level from the univariable models.
Variables remaining in the final models were signifi-
cant at a 5 0.05 level. Estimates for hazard ratios
(HR) and corresponding 95% confidence intervals
(CI) were obtained for each significant prognostic
factor. All P-values are 2 sided. All analyses were run
using Stata 10.1, Stata Corporation, College Station,
TX.P-values based onGray’s test were estimated using
R-project version 2.8.1, The R Foundation for Statisti-
cal Computing, 2008.RESULTS
Patient Characteristics
The baseline characteristics of 72 consecutive
patients included in this analysis are shown in Table 1.
The 2 ATG groups did not differ significantly for age,
histologic diagnosis, donor source, KPS, comorbidity
scores, donor/recipient CMV status, and stem-cell
dose infused. Approximately 25% of the patients ineach group received allografts from HLA-mismatched
unrelated donors. More patients in the r-ATG group
had high-risk disease at the time of transplantation
(P 5 .02), whereas a higher proportion of R-ATG
patients received filgrastim (granulocyte-colony
stimulating factor [G-CSF]) to promote neutrophil
engraftment (P5 .001). Routine use of G-CSF admin-
istration following allografting was discontinued at our
center (in October 2006), after the publication of large
registry data showing no improvement in allogeneic
transplantation outcomes with growth factor adminis-
tration [28].
Engraftment and Chimerism
Median time to neutrophil engraftment was signif-
icantly longer in the r-ATG group compared to the
R-ATG group (18 vesus 15 days; P 5 .01), likely
because of the omission of G-CSF in the r-ATG group
(Table 2). A trend for longer median time to platelet
engraftment was seen in R-ATG group compared to
the r-ATG group (17.5 versus 15 days; P 5 .06). One
patient each in bothgroups experienced secondary graft
failure, which resolved with G-CSF administration.
One R-ATG patient had secondary graft rejection,
with no such events observed in the r-ATG group. Pri-
mary graft failure was not observed. Rates of complete
donor-cell chimerism at days 130, 160, 1180, and
1360 for R-ATG patients were 59%, 63%, 84%, and
91%, respectively, and for r-ATG patients were 43%,
78%, 92%, and 100%, respectively (P5NS).
GVHD
All 72 patients were evaluable for aGVHD
(Table 3). The median time to onset of aGVHD was
44 days and 38 days for the R-ATG and r-ATG
groups, respectively. While accounting for competing
events, the day 1120-cumulative incidence of grade
II-IV aGVHD was 32% for R-ATG group and 27%
for r-ATG group (P 5 .73) (Figure 1A). The day
1120-cumulative incidence of grade III-IV aGVHD
for R-ATG patients and r-ATG patients was 23%
and 11%, respectively (P 5 .28) (Figure 1B). On
univariate analysis, baseline diagnosis of lymphoma
(Hodgkin [HL] and non-Hodgkin [NHL]) was the
only variable associated with aGVHD (HR 5 3.44;
95% CI 5 1-11; P 5 .04).
Sixty-three patients surviving for at least 100 days
posttransplantation were evaluable for cGVHD
(R-ATG group 5 34, r-ATG group 5 29) (Table 3).
The median time to onset of cGVHD for R-ATG
and r-ATG groups was 207 days and 160 days respec-
tively. The day 1400-cumulative incidence of
cGVHD was 44% (n 5 15) for R-ATG group and
61% (n 5 13) for r-ATG group (P 5 .09)
(Figure 1C). The day 1400-cumulative incidence of
extensive cGVHD for the patients in R-ATG group
Table 2. Engraftment Kinetics and Donor-Cell Chimerism
Posttransplantation
ATG
(7.5 mg/kg)
ATG
(6 mg/kg) P-Value
Neutrophil engraftment
(days), median (range)
15 (12-20) 18 (8-32) .01
Platelet engraftment
(days), median (range)
17.5 (10-292) 15 (10-49) .06
Secondary graft failure 1 1 .99
Secondary graft rejection 1 — NA
Day +30 chimerism; median
T cell 97% 91.5% .15
Myeloid 100% 100% .78
Day +90 chimerism; median
T cell 99% 100% .24
Myeloid 100% 100% .76
Day +180 chimerism; median
T cell 100% 100% .56
Myeloid 100% 100% .03
Day +360 chimerism; median
T cell 100% 100% .84
Myeloid 100% 100% .11
ATG indicates antithymocyte globulin.
Table 1. Patient Characteristics at the Time of Transplantation
ATG (7.5 mg/kg) N 5 39 ATG (6 mg/kg) N 5 33 P-Value
Median age; years (range) 56 (24-70) 55 (24-69) .66
Male (%) 71.8 63.6 .61
Diagnosis
AML/MDS 18 (46.2%) 9 (27.3%) .06
NHL/Hodgkin disease 12 (30.8%) 9 (27.3%)
Chronic lymphocytic leukemia 4 (10.3%) 12 (36.4%)
Others 5 (12.8%) 3 (9.1%)
Disease risk‡
Standard risk 11 (28%) 2 (6%) .02
High risk 28 (72%) 31 (94%)
Prior autografting 6 (15%) 1 (3%) .11
Donors
Sibling 5 (12.8%) 3 (9.1%) .71
Unrelated 34 (87.2%) 30 (90.9%)
Degree of HLA match
8/8 match* 31 (79%) 29 (87%) .34
10/10 match† 29 (74%) 25 (75%) .99
Median KPS; (range) 90 (70-100) 90 (80-100) .17
Median HCT-CI; (range) 1 (0-4) 2 (0-4) .11
Cytomegalovirus status
Patient and/or donor seropositive 27 (69.2%) 22 (66.7%) .99
Both patient and donor seronegative 12 (30.8%) 11 (33.3%)
Graft source
Bone marrow 4 (10.3%) — .12
Peripheral blood stem cells 35 (89.7%) 33 (100%)
Patients receiving G-CSF 29 (74.4%) 11 (33.3%) .001
Median CD34+ cell dose (106 cells/kg recipient), (range) 7.02 (0.69-10.2) 7.2 (2.13-10.0) .93
Median CD3+ cell dose (107 cells/kg recipient) (range) 2.33 (0.19-4.24) 2.32 (0.45-4.83) .64
AML indicates acute myelogenous leukemia; ATG. antithymocyte globulin; G-CSF, granulocyte colony-stimulating factor; KPS, Karnofsky performance
score; HCT-CI, Hematopoietic cell transplantation-comorbidity index; HLA, human leukocyte antigen; MDS, myelodysplastic syndrome; NHL, non-
Hodgkin lymphoma.
*8/8 match defined by high-resolution allele-level matching at HLA-A, -B, -C and -DRB1.
†10/10 match defined by high-resolution allele-level matching at HLA-A, -B, -C, -DRB1, and -DQB1.
‡Patients with chronic myelogenous leukemia in first chronic phase, acute leukemia in first complete remission, myelodysplastic syndrome with refrac-
tory anemia, or refractory anemia with ringed sideroblasts were considered to have low-risk disease. All other patients were placed in the high-risk
disease category.
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versus 34% (n 5 4), respectively (P 5 .89)
(Figure 1D). On univariable analysis, baseline diagno-
sis of CLL was the only variable associated with
cGVHD (HR 5 2.82; 95% CI 5 1-7.8; P 5 .04).
Infectious Complications
Compared to the R-ATG group, the patients in
the r-ATG group had significantly fewer episodes of
CMV reactivations (64.1% versus 30.3%; P 5 .005)
and bacterial infections (56.4% versus 18.2%; P 5
.001) (Table 4). There was a nonsignificant trend to
less BK-virus-associated hemorrhagic cystitis in the
r-ATG cohort compared to R-ATG patients (9.1%
versus 25.6%; P 5 .12) (Table 4). In the R-ATG
group 2 patients developed posttransplant lymphopro-
liferative disorder (PTLD), and 2 additional patients
developed adenoviral infections, whereas no such
events were seen in the r-ATG group. Three and 1
invasive fungal infections were reported in the
R-ATG and r-ATG patients, respectively.
NRM and Relapse Rate
Median follow-up of surviving patients following
HSCT is 15 months. The day 100-cumulative inci-dence of NRM rate was significantly lower in r-ATG
group compared to R-ATG group (0% versus 7.7%;
P 5 .03). Similarly, the 1-year cumulative incidence
of NRMwas significantly lower in r-ATG group com-
pared to R-ATG group (3% versus 18%; P 5 .03)
Table 3. Assessment of Graft-versus-Host Disease According
to Dose of Antithymocyte Globulin Used
ATG (7.5 mg/kg)
N 5 39
ATG (6 mg/kg)
N 5 33 P-Value
Rates of acute GVHD*; %(N)
Grade I-IV 41% (16) 48.4% (16) .52
Grade II-IV 30.7% (12) 24.2% (8) .53
Grade III-IV 20.5% (8) 9% (3) .17
Cumulative incidence of acute
GVHD at day +120† (%)
Grade II-IV 27% 32% .73
Grade III-IV 23% 11% .28
Rates of chronic GVHD;* %(N)
Overall chronic GVHD 44.1% (15) 44.8% (13) .95
Limited chronic GVHD 8.8% (3) 31% (9) .02
Extensive chronic GVHD 35.2% (12) 13.7% (4) .05
Cumulative incidence of chronic
GVHD at day +400† (%)
Overall chronic GVHD 44% 61% .09
Limited chronic GVHD 9% 44% .01
Extensive chronic GVHD 40% 34% .89
GVHD indicates graft-versus-host disease; ATG, antithymocyte globulin.
*Represents simple rates of GVHD to provide comparison with studies
not reporting cumulative incidence of GVHD.
†Represents cumulative incidence of GVHD (at specified time points),
while adjusting for competing events (for details please refer to statisti-
cal methods).
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variable was significantly associated with NRM risk.
Causes of NRM are listed in Table 5.
At last follow-up20patients relapsed (R-ATG5 12;
r-ATG 5 8). The cumulative incidence of relapse for
R-ATGand r-ATGpatientswas not significantly differ-
ent (P 5 .85); the 1- and 2-year rates for the 2 groups
were28%versus 25%and25%versus31%, respectively
(Figure 2B). On univariate analysis baseline diagnosis of
CLL (HR5 0.09; 95%CI5 0.01-0.68;P5 .02)was the
only factor associated with the relapse risk.OS and PFS
At last follow-up 49 patients were alive (R-ATG
group 5 21, r-ATG group 5 28). Patients in the
r-ATG group showed a trend for better 1-year OS
compared to patients in the R-ATGgroup (84%versus
64%; log-rank P 5 .07) (Figure 3A; online only); the
2-year expected OS rates were 84% and 55%, respec-
tively. Univariate analysis identified rabbit ATG dose
(HR 5 2.40; P-value 5 0.08), baseline diagnosis of
CLL (HR 5 0.11; p-value 5 0.03), and KPS $90
(HR 5 0.50; P-value 5 0.09) as variables of interest
for multivariable analysis. However, none of these
variables demonstrated independent prognostic signif-
icance on multivariate Cox regression analysis
(P . .05). The expected 1-year PFS rates were 53%
and 71% for patients in R-ATG group and those
in r-ATG group, respectively (log-rank P 5 .12)
(Figure 3B; online only). The corresponding estimates
of 2-year PFS rates were 42%and 71%, respectively. In
a multivariable analysis, baseline diagnosis of CLL
(HR 5 0.10; 95% CI 5 0.02-0.45; P 5 .003) andKPS $90 (HR 5 0.91; 95% CI 5 0.85-0.97;
P 5 .008) were the only factors independently associ-
ated with a better PFS.DISCUSSION
As part of our continuous quality improvement
program, we sought to reduce the risk of infectious
complications and NRM observed in recipients of
mostly unrelated RIC allografts by means of a planned
dose reduction of rabbit ATG associated with our
SOC protocol. We then retrospectively analyzed the
impact of this modest ATG dose reduction on clinical
outcomes and have made several interesting observa-
tions. First, our data support that a relatively small
ATG dose reduction to 6 mg/kg had no deleterious
effect on engraftment kinetics or donor chimerism.
Second, the lower ATG dose did not appear to
increase the risk of either aGVHD or cGVHD. Third,
the dose reduction was associated with significantly
less viral and bacterial infections. These results ulti-
mately translated into a reduction in NRM and similar
OS and PFS for patients that received the lower dose of
ATG compared with those that received the higher
dose. These findings we feel validate the importance
of continuous quality monitoring associated with
blood and marrow transplant programs.
Over the last 2 decades, various investigators have
reported encouraging transplantation outcomes with
the inclusion of ATG in transplant conditioning regi-
mens [6,9,29-31], whereas others have reported com-
parable transplantation results without the use of
ATG [32,33]. These divergent data have created
considerable controversy about the role (if any) and
indications of ATG use with allogeneic HSCT. The
lack of randomized data addressing the role of ATG
with transplant conditioning has been the key factor
fueling this controversy for decades. Recently, a phase
III trial, reported in abstract form only [34], has shown
significant reduction in the rates of aGVHD and
cGVHD for patients randomized to receiving ATG
with transplant conditioning. This key study supports
the use of ATG, at least for patients receiving
unrelated donor allografts followingMA conditioning.
ATG prevents development of GVHD, not only
through in vivo donor effector TCD, but also via pleio-
tropic effects on the immune system including depletion
and modulation of antigen presenting cells, modulation
of cell surface molecules that mediate leukocyte/endo-
thelium interactions and induction of regulatory T cells
[35-40]. In addition to dose intensity, the efficacy of
ATG in preventing GVHD is intricately dependent on
the type of ATG preparation used and on the timing
of ATG administration beforeHSCT [1,17,41]. Unfor-
tunately, in the majority of the studies assessing ATG
dose intensity, different ATG doses were administered
ATG (6.0 mg/kg)
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Figure 1. Cumulative incidence of GVHD according to the ATG dosage group. (A) cumulative incidence of grade II-IV aGVHD. (B) Cumulative
incidence of grade III-IV aGVHD. (C) Cumulative incidence of cGVHD. (D) Cumulative incidence of extensive cGVHD. Solid curves represent patients
receiving ATG at 6.0 mg/kg, whereas the dashed curves represent patients getting the 7.5 mg/kg ATG dose.
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cacy results difficult [6,17,20]. Thus, in our study, when
we elected to reduce the 7.5 mg/kg total dose of rabbit
ATG in patients undergoing RIC HSCT, we decided
to keep the ATGpreparation and administration sched-
ule uniform, to facilitate comparison of the 2 ATG dose
levels.This allowedus to investigate the impact of an ap-
parently lowerATGdose onGVHDcontrol rates, graft
function, infection, and other transplantation outcomes.Table 4. Infectious Complications Postallogeneic Trans-
plantation
ATG (7.5 mg/kg)
N (%)
ATG (6 mg/kg)
N (%) P-Value
CMV reactivation 25 (64.1) 10 (30.3) .005
EBV reactivation 10 (25.6) 7 (21.2) .78
Adenovirus infections 2 (5.1) 0 .49
BK-virus associated
hemorrhagic cystitis
10 (25.6) 3 (9.1) .12
Bacterial infections 22 (56.4) 6 (18.2) .001
Gram-positive bacteria 14 3
Gram-negative bacteria 8 3
Invasive fungal infections 3 (7.7) 1 (3) .62
Aspergillus fumigatus 1 1
Histoplasma Capsulatum 1 —
Candida albicans 1 —
CMV indicates cytomegalovirus; EBV, Epstein-Barr virus; ATG,
antithymocyte globulin.Numerous studies have shown the efficacy of ATG
for GVHD prophylaxis [4,6-10,19,31,42]. However,
higher ATG doses (thymoglobulin dose-equivalents
$7.5-15 mg/kg) have been associated with increased
risk of relapse, infectious complications, and NRM
[8,31,43]. Despite these data, only a handful of studies
have attempted to define the optimal dose intensity
of ATG. Bacigalupo et al. [6] reported outcomes of
patients receiving either 15 mg/kg or 7.5 mg/kg of
ATG (along with MA conditioning) compared to pa-
tients not receiving thymoglobulin. Although no direct
dose comparisons were planned in that study, rates of
aGVHD appeared worse (69%) with the lower 7.5
mg/kg ATG dose, compared to the higher 15 mg/kg
dose (37%). However, the 15 mg/kg ATG was associ-
ated with significantly more lethal infectious complica-
tions.
Meijer et al. [18] compared progressively lower
doses of ATG (8 mg/kg, 6 mg/kg, and 4 mg/kg) in pa-
tients undergoing NA HSCT, and reported signifi-
cantly higher rates of aGVHD and trends toward
higher rates of cGVHD with the lower ATG doses.
A limitation of this study, however, was the relatively
small number of patients receiving the lower 4 mg/
kg (n 5 9) and 6 mg/kg (n 5 13) ATG dose. In con-
trast, Ayuk et al. [17] reported no difference in
ATG (6.0 mg/kg)
ATG (7.5 mg/kg)
Gray's test p-value = 0.030.00
0.10
0.20
0.30
0.40
A
B
Cu
m
ul
at
ive
 In
cid
en
ce
0 100 200 300 400 500 600 700 800
Days Post Transplant
Cumulative Incidence of non -relapse mortality
ATG (6.0 mg/kg)
ATG (7.5 mg/kg)
Gray's test p-value = 0.85
0.00
0.05
0.10
0.15
0.20
0.25
0.30
Cu
m
ul
at
ive
 In
cid
en
ce
0 50 100 150 200 250 300 350 400
Days Post Transplant
Cumulative Incidence of Relapse
Figure 2. (A) Cumulative incidence of NRM according to the ATG dos-
age group. (B) Cumulative incidence of disease relapse according to the
ATG dosage group. Solid curves represent patients receiving ATG at 6.0
mg/kg, whereas the dashed curves represent patients getting the 7.5 mg/
kg ATG dose.
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ferent doses of ATG-Fresenius (30 mg/kg versus 60
mg/kg) with MA conditioning. In the only series com-
paring ATG dose intensity in patients undergoing
(matched sibling) RIC-HSCT, Mohty et al. [20]
observed a significant increase in rates of aGVHD
and cGVHD when ATG dose was reduced from
$7.5 mg/kg to 2.5 mg/kg. Our analysis, in contrast,Table 5. Causes of Nonrelapse mortality According to Dose
of Antithymocyte Globulin Administered
Cause of death
ATG (7.5 mg/kg)
N 5 11
ATG (6 mg/kg)
N 5 1
GVHD with sepsis 1 1
GVHD without sepsis 1 —
Sepsis 1 —
Posttransplant lymphoproliferative
disorder
2 —
Second malignancy 2 —
Adenoviral pneumonia 1 —
Cerebral toxoplasmosis 1 —
JC-viral progressive
multifocal leukoencephalopathy
1 —
Cardiac toxicity 1 —
ATG indicates antithymocyte globulin; GVHD, graft-versus-host disease.shows that a less aggressive ATG dose reduction may
not compromise aGVHD control. This is a potentially
important observation given that most of our patients
received allografts from unrelated donors, had high-
risk disease at baseline, and approximately a quarter
of the patients received transplants from HLA-mis-
matched unrelated donors.
Significantly fewer r-ATG patients in our analysis
received G-CSF postallografting, which may explain
acceptable aGVHD control rates in this group. It
must be pointed out, however, that although some
studies suggest an increased risk of aGVHD with
post-HSCT G-CSF administration [44], others have
found no such association [28,45]. Moreover, in our
analyses G-CSF was not independently associated
with an increased risk of aGVHD (P 5 .63). We also
found no negative correlation between attainment of
full donor chimerism and lower ATG dose. The
median time to neutrophil engraftment was longer in
the r-ATG patients, which is likely because of less
frequent use of G-CSF in this group.
In our study, the higher 7.5 mg/kg ATG dose was
associated with frequent CMV reactivations, bacterial
infections, and lethal infectious complications, leadingATG (6.0 mg/kg)
ATG (7.5 mg/kg)
Log-rank test p-value = 0.12
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Figure 3. OS and PFS according to ATG dosage group. (A) Kaplan-
Meier estimates of OS following allogeneic transplantation, (B) Kaplan-
Meier estimates of PFS following allogeneic transplantation. Solid curves
represent patients receiving ATG at 6.0 mg/kg, whereas the dashed
curves represent patients getting the 7.5 mg/kg ATG dose.
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previous studies, where the benefit of fewer infectious
complications attained with lower ATG doses (2.5-4
mg/kg) was offset by unacceptable rates of GVHD
[18,20,43], we demonstrated here that ‘‘conservative’’
ATG dose deescalation to 6 mg/kg can significantly
reduce the rates of infectious events and NRM while
maintaining acceptable GVHD control rates. The
1-year NRM rate of 3% in the r-ATG cohort is
encouraging, especially when considering the high-
risk characteristics of patients included at baseline.
In summary, our findings suggest that for patients
undergoing RIC HSCT, a total dose of ATG as low as
6 mg/kg dose appears to be associated with significantly
fewer infectious complications and lower rates ofNRM,
without compromisingGVHDcontrol or survivalwhen
compared to higher administered doses. Our data
highlight the fact that the relative ATG dose intensity
has significant impact on transplantation outcomes,
underscoring the need to systematically determine and
employ the ATG dose with ‘‘best’’ therapeutic index,
not only in clinical practice, but also in future clinical
trials. We must acknowledge that these findings were
made in the context of a quality improvement effort
rather than a prospective hypothesis driven research
protocol. It also involved a heterogeneous group of
high-risk patients. Nevertheless, the present study is
one of the larger analyses that have attempted to address
the question of defining the best therapeutic index for
ATG in patients undergoingHSCT. Based on our anal-
ysis, we conclude that validation of these results would
be warranted in a larger, prospective trial evaluating
the impact of varying doses of ATG.ACKNOWLEDGMENTS
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